# Pulmonary Embolism Thrombolysis Selection

Select reperfusion therapy by hemodynamic status, RV injury, and bleeding risk: systemic thrombolysis remains standard for high-risk PE, whereas anticoagulation with monitored rescue escalation is preferred for most normotensive intermediate-risk patients.

**Clinical question:** Which patients with acute pulmonary embolism should receive systemic thrombolysis, catheter-directed therapy, or anticoagulation alone?

Updated: 2026-09-15T21:57:51.021909+00:00

## What matters in practice
- Treat hemodynamic instability as high-risk PE; systemic thrombolysis is the established reperfusion treatment when bleeding risk permits. [1][7][10][12]
- Do not use routine up-front systemic thrombolysis for normotensive intermediate-risk PE; anticoagulation is first-line because reduced hemodynamic deterioration is offset by major bleeding and intracranial hemorrhage. [4][11][12][14][23]
- Classify normotensive patients with an elevated PESI or sPESI plus both RV dysfunction and elevated troponin as intermediate-high risk; monitor closely for decompensation and use rescue reperfusion selectively. [10][14]
- Consider catheter-directed therapy when high-risk or selected intermediate-high-risk PE requires reperfusion but systemic thrombolysis has failed, is contraindicated, or carries unacceptable bleeding risk; randomized comparative evidence remains limited. [1][9][15]

## Separate high-risk PE from normotensive PE before selecting thrombolysis

Blood pressure and shock status determine whether immediate reperfusion is needed.

Classify PE as high risk when there is hemodynamic instability. The AHA framework defines massive PE as systolic blood pressure below 90 mm Hg for more than 15 minutes or a requirement for inotropic support. In this group, systemic thrombolysis is the established reperfusion strategy when there is no prohibitive bleeding risk. [7][10][12]

A normotensive patient is not automatically low risk. Obtain a validated clinical severity score such as PESI or sPESI, assess RV function by echocardiography or CT, and measure troponin. An elevated PESI or sPESI combined with both RV dysfunction and elevated troponin identifies intermediate-high-risk PE; an elevated score with neither or only one positive RV injury marker is intermediate-low risk. [4][10][14]

For intermediate-high-risk PE, begin systemic anticoagulation and monitor for hemodynamic deterioration rather than giving routine up-front systemic thrombolysis. The key operational distinction is that thrombolysis becomes a rescue or individualized escalation decision in a normotensive patient, but an immediate reperfusion decision in high-risk PE. [1][7][14][23]
- High risk: hemodynamic instability, including systolic blood pressure below 90 mm Hg for more than 15 minutes or need for inotropic support; pursue urgent reperfusion assessment. [7][10]
- Intermediate-high risk: elevated PESI or sPESI, RV dysfunction on imaging, and elevated troponin; anticoagulate and observe closely for deterioration. [10][14]
- Intermediate-low or low risk: anticoagulation is the treatment pathway rather than thrombolysis. [7][10][11]

*Risk category determines whether reperfusion is immediate, rescue-based, or not routinely indicated. [7][10][12][14]*

| Clinical category | Required discriminators | Initial thrombolysis decision |
| --- | --- | --- |
| High-risk PE | Hemodynamic instability; AHA massive criterion includes systolic blood pressure <90 mm Hg for >15 minutes or inotropic support. [10] | Use systemic thrombolysis when not contraindicated; consider catheter-based or surgical reperfusion when thrombolysis is contraindicated or unsuccessful. [7][12][20] |
| Intermediate-high-risk PE | Normotension, elevated PESI or sPESI, RV dysfunction on imaging, and elevated troponin. [10][14] | Anticoagulation plus close monitoring; do not give routine up-front systemic thrombolysis. Escalate selectively with clinical deterioration or when individualized reperfusion benefit outweighs bleeding risk. [12][14][23] |
| Intermediate-low-risk PE | Normotension, elevated PESI or sPESI, with none or one of RV dysfunction or troponin elevation. [10] | Anticoagulation; no routine thrombolysis. [7][11] |
| Low-risk PE | PESI class I-II or sPESI 0 with normal RV assessment in the ESC scheme. [10] | Anticoagulation; thrombolysis is not indicated routinely. [7][10] |

## Reserve systemic thrombolysis for high-risk PE and selected rescue scenarios

The principal tradeoff is rapid hemodynamic benefit versus major and intracranial bleeding.

Systemic thrombolysis rapidly improves RV function and hemodynamic parameters and is recommended for high-risk PE. In a patient with shock or sustained hypotension, do not wait for a progressive biomarker profile before evaluating contraindications and delivering reperfusion therapy. [7][12][22]

For normotensive intermediate-risk PE, systemic thrombolysis can reduce death or hemodynamic deterioration, but bleeding limits routine use. In PEITHO, tenecteplase was associated with major bleeding in 6.3% and intracranial hemorrhage in 2.0%, versus 1.5% and 0.2%, respectively, with heparin alone. [4][11]

The bleeding signal is consistent across broader comparative evidence. Compared with anticoagulation alone, systemic thrombolysis was associated with higher major bleeding (odds ratio 2.16) and intracranial hemorrhage (odds ratio 2.26), without a mortality difference in a meta-analysis including 81,705 patients. These findings support avoiding routine lysis in stable intermediate-risk patients even when RV dysfunction is present. [12]

Use systemic thrombolysis as rescue therapy when a patient initially managed as intermediate-high risk develops hemodynamic decompensation, provided bleeding risk is acceptable. Escalate the decision through a multidisciplinary PE team when available, particularly if rescue lysis, catheter-directed therapy, surgical embolectomy, or mechanical circulatory support may be needed. [9][14][15]
- Immediate systemic thrombolysis: high-risk PE with hemodynamic instability and no contraindication to thrombolysis. [1][7][12]
- Avoid routine up-front systemic thrombolysis: normotensive intermediate-risk PE, including intermediate-high-risk disease. [12][14][23]
- Use individualized rescue consideration: intermediate-high-risk PE with hemodynamic deterioration during anticoagulation. [14][15]
- Treat advanced age as a bleeding-risk amplifier; one report cited major bleeding of 12.93% in patients older than 65 years receiving systemic thrombolysis. [5]

*Observed outcomes explain why systemic thrombolysis is not routine for stable intermediate-risk PE. [4][11][12]*

| Comparison | Potential benefit | Bleeding tradeoff | Selection consequence |
| --- | --- | --- | --- |
| Tenecteplase versus heparin in submassive PE | Prevented death or hemodynamic deterioration. [11] | Major bleeding: 6.3% versus 1.5%; intracranial hemorrhage: 2.0% versus 0.2%. [4] | Do not use as routine treatment for normotensive intermediate-risk PE. [11][14] |
| Systemic thrombolysis versus anticoagulation in pooled acute PE studies | No mortality difference in the cited comparative meta-analysis. [12] | Major bleeding OR 2.16; intracranial hemorrhage OR 2.26. [12] | Preserve systemic thrombolysis for high-risk PE or selected rescue use. [12] |

## When catheter-directed therapy is a reasonable alternative to systemic thrombolysis

Catheter intervention is an escalation option, not routine first-line therapy for stable PE.

Consider catheter-directed therapy (CDT) when a patient with high-risk PE needs reperfusion but systemic thrombolysis is contraindicated or has failed. CDT is also used in selected intermediate-high-risk patients with hemodynamic decompensation or substantial risk for deterioration when bleeding risk makes systemic thrombolysis unattractive. [9][15]

Catheter-directed thrombolysis uses less than one quarter of the systemic thrombolytic dose, offering a rationale for reduced systemic exposure. However, device-specific selection should not be based on an assumption of proven superiority: randomized comparative evidence against anticoagulation or systemic thrombolysis remains limited. [1][15]

Comparative pooled data are hypothesis-supporting but not definitive. In a meta-analysis of 45 studies, CDT versus anticoagulation was associated with lower mortality (odds ratio 0.55) but higher major bleeding (odds ratio 1.84); systemic thrombolysis had higher mortality and intracranial hemorrhage than CDT in that analysis. Observational study contribution and mixing of intermediate- and high-risk populations limit direct treatment ranking. [1][12]

Use surgical embolectomy when fibrinolysis is contraindicated or unsuccessful, especially when immediate mechanical reperfusion is required. Mechanical circulatory support may be part of the strategy for life-threatening high-risk PE, but selection should occur in a center able to coordinate interventional, surgical, and critical care capabilities. [14][15][20]
- CDT is most defensible when reperfusion is necessary and systemic thrombolysis is contraindicated or has failed. [9][15]
- Do not substitute CDT automatically for anticoagulation in all intermediate-high-risk PE; its role beyond anticoagulation remains under active study. [1][15]
- Surgical embolectomy is a reperfusion alternative after failed fibrinolysis or when fibrinolysis is contraindicated. [20]

### Avoid procedure-driven escalation in stable patients

RV dysfunction alone does not mandate a catheter procedure. First verify whether the patient meets intermediate-high-risk criteria with both RV dysfunction and troponin elevation, then determine whether there is actual hemodynamic deterioration despite anticoagulation. In the absence of instability, the established first-line pathway remains anticoagulation with surveillance. [10][14][15]

*Reperfusion modality should match urgency, bleeding risk, and feasibility. [7][9][12][15][20]*

| Modality | Best-supported role | Key limitation or tradeoff |
| --- | --- | --- |
| Systemic thrombolysis | High-risk PE with hemodynamic instability and no prohibitive bleeding risk. [7][12] | Increases major bleeding and intracranial hemorrhage versus anticoagulation; routine use is not supported in stable intermediate-risk PE. [12] |
| Catheter-directed thrombolysis or catheter intervention | High-risk or selected intermediate-high-risk PE needing escalation when systemic thrombolysis is contraindicated, has failed, or presents unacceptable bleeding concern. [9][15] | Randomized evidence comparing CDT with anticoagulation and systemic thrombolysis remains limited. [15] |
| Surgical embolectomy | Fibrinolysis contraindicated or unsuccessful. [20] | Requires immediate surgical capability and patient-specific procedural assessment. [20] |
| Anticoagulation alone | Low-risk, intermediate-low-risk, and initially stable intermediate-high-risk PE. [7][11][14] | Requires close surveillance in intermediate-high-risk PE because deterioration may require rescue reperfusion. [14] |

## Monitor intermediate-high-risk PE for deterioration rather than treating the imaging result alone

The purpose of monitoring is to identify the patient who converts from a surveillance pathway to rescue reperfusion.

Admit intermediate-high-risk patients to a setting that permits frequent blood-pressure and perfusion reassessment. Repeat clinical evaluation promptly for hypotension, shock, or a need for inotropic support, because these findings reclassify the patient into a high-risk pathway and trigger immediate reassessment for reperfusion. [10][14]

Use the initial RV imaging and troponin results for risk designation, not as isolated indications for lysis. Echocardiography, CT, and cardiac biomarkers add prognostic discrimination to PESI or sPESI; patients designated low risk by clinical score but with RV dysfunction on echocardiography or CT have higher odds of all-cause mortality in pooled data. [4][10]

For a stable patient with RV dysfunction and elevated troponin, reassess bleeding risk before any rescue intervention. The benefit of preventing deterioration must be weighed against the excess intracranial hemorrhage and major bleeding observed with systemic thrombolysis in intermediate-risk PE. [4][11][12]
- At presentation: calculate PESI or sPESI, assess RV function by CT or echocardiography, and measure troponin. [4][10]
- If blood pressure falls below 90 mm Hg for more than 15 minutes or inotropic support becomes necessary, manage as high-risk PE and reassess urgent reperfusion options. [10]
- If the patient remains stable, continue anticoagulation rather than escalating solely because RV dysfunction or troponin is positive. [12][14]

*A change in hemodynamics—not persistent RV injury markers alone—drives rescue reperfusion consideration. [10][12][14]*

| Finding during anticoagulation | Interpretation | Next action |
| --- | --- | --- |
| Persistent normotension in intermediate-high-risk PE | No conversion to high-risk PE. [10][14] | Continue anticoagulation and close clinical monitoring; do not use routine systemic thrombolysis. [12][14] |
| Systolic blood pressure <90 mm Hg for >15 minutes or inotropic requirement | Hemodynamic instability; high-risk PE criterion. [10] | Urgently select systemic thrombolysis if feasible or catheter/surgical reperfusion when lysis is contraindicated or unsuccessful. [7][9][20] |
| RV dysfunction or positive troponin without hypotension | Supports intermediate-risk stratification but is not an isolated indication for routine lysis. [10][12] | Use clinical surveillance and reassess if hemodynamic deterioration occurs. [14] |

## Common questions

### Does right ventricular dysfunction alone justify thrombolysis in a normotensive patient?

No. RV dysfunction should be integrated with PESI or sPESI and troponin for risk classification. Routine systemic thrombolysis in stable intermediate-risk PE is limited by excess major bleeding and intracranial hemorrhage. [10][12][14]

### When should a PE team be involved?

Activate multidisciplinary discussion when high-risk PE requires reperfusion, when intermediate-high-risk PE deteriorates, or when systemic thrombolysis is contraindicated, fails, or must be weighed against catheter or surgical options. [9][14][15][20]

## References
1. Catheter-Directed Thrombolysis for Intermediate- and High-Risk Pulmonary Embolism | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/catheter-directed-thrombolysis-intermediate-high-risk-pulmonary-embolism-nejm-jw.NA56452
2. Catheter-directed thrombolysis to treat acute pulmonary thrombosis ... — casereports.bmj.com — https://casereports.bmj.com/content/13/8/e237046
3. Catheter-directed thrombolysis versus anticoagulation ... - Open Heart — openheart.bmj.com — https://openheart.bmj.com/content/13/2/e004250
4. Management dilemmas in acute pulmonary embolism - Thorax — thorax.bmj.com — https://thorax.bmj.com/content/69/2/174
5. Massive pulmonary embolism treated with low-dose thrombolysis on ... — casereports.bmj.com — https://casereports.bmj.com/content/15/4/e248125
6. Deep vein thrombosis and pulmonary embolism in the military patient — militaryhealth.bmj.com — https://militaryhealth.bmj.com/content/jramc/161/3/288.full.pdf
7. Pulmonary embolism - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/116
8. based prognostic factors associated with mortality in pulmonary ... — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/early/2026/05/18/thorax-2025-223933.full.pdf
9. Innovation in Catheter-Directed Therapy for Intermediate-High-Risk and High-Risk Pulmonary Embolism | JACC: Cardiovascular Interventions — www.jacc.org — https://www.jacc.org/doi/abs/10.1016/j.jcin.2024.07.033
10. 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM ... - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2025.11.005
11. Mortality and bleeding associated with the management of sub-massive pulmonary embolism: a systematic review and Bayesian network meta-analysis | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-023-34348-9
12. Efficacy and Safety of Anticoagulation, Catheter-Directed Thrombolysis, or Systemic Thrombolysis in Acute Pulmonary Embolism — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jcin.2023.07.042
13. Large-Bore Mechanical Thrombectomy Versus Catheter-Directed ... — www.ahajournals.org — https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.072364
14. Intermediate-high risk pulmonary embolism: When teamwork really ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2666572723000287
15. Innovation in Catheter-Directed Therapy for Intermediate-High-Risk and High-Risk Pulmonary Embolism — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1936879824010306
16. Has systemic thrombolysis run its course? A systematic review and network meta-analysis of patients with intermediate- and high-risk pulmonary embolism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0049384825002531
17. Systematic Review: The Role of Thrombolysis in Intermediate-Risk Pulmonary Embolism - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0736467919304755
18. The Prognostic Value of Troponin in Acute Pulmonary Embolism: A ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1002/ccd.70243
19. Management of intermediate‐risk pulmonary embolism ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.12612
20. Comparison of interventions for intermediate to high‐risk pulmonary ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/ccd.30745
21. Systemic thrombolytic therapy for acute pulmonary embolism — academic.oup.com — https://academic.oup.com/eurheartj/article/36/10/605/514452
22. Ultrasound-assisted thrombolysis for acute pulmonary embolism — academic.oup.com — https://academic.oup.com/eurheartj/article/35/12/758/623552
23. Endovascular management of intermediate-risk pulmonary embolism — academic.oup.com — https://academic.oup.com/ehjopen/article/5/3/oeaf071/8156689
24. Treatment of acute pulmonary embolism: anticoagulation ... — academic.oup.com — https://academic.oup.com/eurheartjsupp/article/28/Supplement_5/v173/8514552

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.